The Neurobiology of Neurotensin

Garth Bissette
Department of Psychiatry and Human Behavior
University of Mississippi Medical Center
Jackson, Mississippi 39216-4505

Charles B. Nemeroff
Department of Psychiatry and Behavioral Science
Emory University School of Medicine
Atlanta, Georgia 30322-4990


  1. Adams M, Brandon E, Chartoff E, Idzerda R, Dorsa D and McKnight G. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proceedings of the National Academy of Sciences of the United States of America. 1997. 94:12157-12161.
  2. Adams M, Dobie D, Merchant K, Unis A and Dorsa D. EEDQ reduces the striatal neurotensin mRNA response to haloperidol. Peptides. 1997. 18:527-535.
  3. Asan E. The catecholaminergic innervation of the rat amygdala. Advances in Anatomy, Embryology & Cell Biology. 1998. 142:1-118.
  4. Atoji Y, Shibata N, Yamamoto Y and Suzuki Y. Distribution of neurotensin-containing neurons in the central nervous system of the pigeon and the chicken. Journal of Comparative Neurology. 1996. 375:187-211.
  5. Augood S, Westmore K and Emson P. Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: a detailed cellular co-expression study. Neuroscience. 1997. 76:763-774.
  6. Azzi M, Boudin H, Mahmudi N, Pelaprat D, Rostene W and Berod A. In vivo regulation of neurotensin receptors following long-term pharmacological blockade with a specific receptor antagonist. Molecular Brain Research. 1996. 42:213-221.
  7. Bachelet C, Scarceriaux V, Rostene W and Pelaprat D. Evidence for neurotensin autoreceptors and relationship of neurotensin and its receptors with tyrosine hydroxylase-positive neurons in rat primary hypothalamic cultures. European Journal of Neuroscience. 1997. 9:1483-1487.
  8. Banker N, Hellmich M, Kim H, Townsend C and Evers B. Src-mediated activation of the human neurotensin/neuromedin N promoter. Surgery. 1997. 122:180-185.
  9. Barbero P, Rovere C, De Bie I, Seidah N, Beaudet A and Kitabgi P. PC5-A-mediated processing of pro-neurotensin in early compartments of the regulated secretory pathway of PC5-transfected PC12 cells. Journal of Biological Chemistry. 1998. 273:25339-25346.
  10. Berger B, Alvarez C and Pelaprat D. Retrosplenial/presubicular continuum in primates: a developmental approach in fetal macaques using neurotensin and parvalbumin as markers. Developmental Brain Research. 1997. 101:207-224.
  11. Betancur C, Canton M, Burgos A, Labeeuw B, Gully D, Rostene W and Pelaprat D. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. European Journal of Pharmacology. 1998. 343:67-77.
  12. Betancur C, Rostene W and Berod A. Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum. Molecular Brain Research. 1997. 44:334-340.
  13. Bissette G, Griff D, Carnes M, Goodman B, Lavine M and Levant B. Apparent seasonal rhythms in hypothalamic neuropeptides in rats without photoperiod changes. Endocrinology 1995. 136:622-628.
  14. Botto J, Chabry J, Nouel D, Paquet M, Seguela P, Vincent J, Beaudet A and Mazella J. Identification in the rat neurotensin receptor of amino-acid residues critical for the binding of neurotensin. Molecular Brain Research. 1997. 46:311-317.
  15. Botto J, Guillemare E, Vincent J and Mazella J. Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor. Neuroscience Letters. 1997. 223:193-196.
  16. Botto J, Vincent J and Mazella J. Existence of two translation initiation sites leading to the expression of two proteins from the rat high-affinity neurotensin receptor cDNA: possible regulation by the 5 end non-coding region. Biochemical Journal. 1997. 324:389-393.
  17. Butler P.D., Printz D.J., DeSanti L., Issa F., Gorman J.M., Carraway R.E., Neurotensin and metabolites in CSF of patients with schizophrenia and controls. Biological Psychiatry 1996. 39: 587-587.
  18. Chalon P, Vita N, Kaghad M, Guillemont M, Bonnin J, Delpech B, Lefur G, Ferrara P and Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Letters. 1996. 386:91-94.
  19. Ciriello J and Zhang T. Cardiovascular effects of neurotensin microinjections into the nucleus of the solitary tract. Brain Research. 1997. 749:35-43.
  20. Conlon J, Adrian T and Secor S. Tachykinins (substance P, neurokinin A and neuropeptide gamma) and neurotensin from the intestine of the Burmese python, Python molerus. Peptides. 1997. 18:1505-1510.
  21. Croci T, Landi M, Gully D, Maffrand J, Le Fur G and Manara L. Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats. British Journal of Pharmacology. 1997. 120:1312-1318.
  22. Dilts R, Novitzki M, Phan T, Corley K and Boadle-Biber M. Neurotensin inhibits the activation of midbrain serotonergic neurons produced by random inescapable sound. Brain Research. 1996. 742:294-298.
  23. Dong Z, Wang X, Zhao Q, Townsend C and Evers B. DNA methylation contributes to expression of the human neurotensin/neuromedin N gene. American Journal of Physiology. 1998. 274:G535-543.
  24. Dubuc I, Sarret P, Labbe-Jullie C, Botto J-M, Honore E, Bourdel E, Martinez J, Costentin J, Vincent J-P, Kitabgi P and Mazella J. Identification of the receptor subtype involved in the analgesic effect of neurotensin. Journal of Neuroscience. 1999. 19: 503-510.
  25. Dufourny L, Warembourg M and Jolivet A. Multiple peptides infrequently coexist in progesterone receptor-containing neurons in the ventrolateral hypothalamic nucleus of the guinea-pig: an immunocytochemical triple-label analysis of somatostatin, neurotensin and substance P. Journal of Neuroendocrinology. 1998. 10:165-173.
  26. Erwin V, Draski L and Deitrich R. Neurotensin levels and receptors in HAS and LAS rat brains: effects of ethanol. Pharmacology, Biochemistry & Behavior. 1996. 54:525-532.
  27. Erwin V, Markel P, Johnson T, Gehle V and Jones B. Common quantitative trait loci for alcohol-related behaviors and central nervous system neurotensin measures: hypnotic and hypothermic effects. Journal of Pharmacology & Experimental Therapeutics. 1997. 280:911-918.
  28. Erwin V, Radcliffe R, Gehle V and Jones B. Common quantitative trait loci for alcohol-related behaviors and central nervous system neurotensin measures: locomotor activation. Journal of Pharmacology & Experimental Therapeutics. 1997. 280:919-926.
  29. Esposito V, De Girolamo P and Gargiulo G. Neurotensin-like immunoreactivity in the brain of the chicken, Gallus domesticus. Journal of Anatomy. 1997. 191:537-546.
  30. Farkas R, Chien PY, Nakajima S and Nakajima Y. Neurotensin and dopamine D2 activation oppositely regulate the same K+ conductance in rat midbrain dopaminergic neurons. Neuroscience Letters. 1997. 231:21-24.
  31. Feifel D, Minor K, Dulawa S and Swerdlow N. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Research. 1997. 760:80-84.
  32. Feifel D, Reza T and Robeck S. Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides. 1997. 18:1457-1460.
  33. Ferraro L, O'Connor W, Antonelli T, Fuxe K and Tanganelli S. Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat. European Journal of Neuroscience. 1997. 9:1838-1846.
  34. Feurle G. Xenin--a review. Peptides. 1998. 19:609-615.
  35. Gehle V and Erwin V. Common quantitative trait loci for alcohol-related behaviors and CNS neurotensin measures: voluntary ethanol consumption. Alcoholism, Clinical & Experimental Research. 1998. 22:401-408.
  36. Gudasheva T, Voronina T, Ostrovskaya R, Zaitseva N, Bondarenko N, Briling V, Asmakova L, Rozantsev G and Seredenin S. Design of N-acylprolyltyrosine "tripeptoid" analogues of neurotensin as potential atypical antipsychotic agents. Journal of Medicinal Chemistry. 1998. 41:284-290.
  37. Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg R, Suaud-Chagny M, Santucci V, Vita N, Pecceu F, Labbe-Jullie C, Kitabgi P, Soubrie P, Le Fur G and Maffrand J. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. Journal of Pharmacology & Experimental Therapeutics. 1997. 280:802-812.
  38. Hakansson M, Brown H, Ghilardi N, Skoda R and Meister B. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. Journal of Neuroscience. 1998. 18:559-572.
  39. Hanson G, Wagstaff J, Merchant K and Gibb J. Psychostimulants and neuropeptide response. Advances in Pharmacology. 1998. 42:1014-1016.
  40. Heaulme M, Leyris R, Le Fur G and Soubrie P. Involvement of potentially distinct neurotensin receptors in neurotensin-induced stimulation of striatal [3H]dopamine release evoked by KCl versus electrical depolarization. Neuropharmacology. 1997. 36:1447-1454.
  41. Hermans E, Geurts M and Maloteaux J. Agonist and antagonist modulation of [35S]-GTP gamma S binding in transfected CHO cells expressing the neurotensin receptor. British Journal of Pharmacology. 1997. 121:1817-1823.
  42. Hermans E, Vanisberg M, Geurts M and Maloteaux J. Down-regulation of neurotensin receptors after ligand-induced internalization in rat primary cultured neurons. Neurochemistry International. 1997. 31:291-299.
  43. Herzig K, Domagk J, Nustede R, Stern M, Bewig B, Cichy W, and Folsch U. Plasma concentrations of cholecystokinin and neurotensin in patients with cystic fibrosis. Scandinavian Journal of Gastroenterology. 1997. 32:315-319.
  44. Huang W and Hanson G. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems. European Journal of Pharmacology. 1997. 332:15-21.
  45. Iwase K, Evers B, Hellmich M, Kim H, Higashide S, Gully D, Thompson J and Townsend C. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer. 1997. 79:1787-1793.
  46. Jolas T and Aghajanian G. Neurotensin and the serotonergic system. Progress in Neurobiology. 1997. 52:455-468.
  47. Lambert P, Ely T, Gross R and Kilts C. Neurotensin induces Fos and Zif268 expression in limbic nuclei of the rat brain. Neuroscience. 1996. 75:1141-1151.
  48. Lan C, Wen C, Tan C, Ling E and Shieh J. Ultrastructural study of phenylethanolamine-N-methyltransferase, corticotropin-releasing factor and neurotensin immunoreactive neurons in the external cuneate nucleus of the gerbil. Brain Research. 1996. 711:211-222.
  49. Le F, Groshan K, Zeng X and Richelson E. Characterization of the genomic structure, promoter region, and a tetranucleotide repeat polymorphism of the human neurotensin receptor gene. Journal of Biological Chemistry. 1997. 272:1315-1322.
  50. Le F, Zeng X and Richelson E. Tetranucleotide repeat polymorphism in the human neurotensin receptor (NT-R) gene. Clinical Genetics. 1997. 51:76-7.
  51. Liegeois J, Bonaventure P, Delarge J and Damas J. Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Neuroscience & Biobehavioral Reviews. 1995. 19:519-531.
  52. Marcos P, Corio M, Dubourg P, Covenas R and Tramu G. Double immunocytochemistry in pre-embedding electron microscopy for the detection of neurotensin and tyrosine hydroxylase in the guinea pig, using two primary antisera raised in the same species. Brain Research. Brain Research Protocols. 1997. 2:1-8.
  53. Marcos P, Covenas R, Narvaez J, Aguirre J, Tramu G and Gonzalez-Baron S. Neuropeptides in the cat amygdala. Brain Research Bulletin. 1998. 45:261-268.
  54. Margeta-Mitrovic M, Grigg J, Koyano K, Nakajima Y and Nakajima S. Neurotensin and substance P inhibit low- and high-voltage-activated Ca2+ channels in cultured newborn rat nucleus basalis neurons. Journal of Neurophysiology. 1997. 78:1341-1352.
  55. Mazella J, Botto J, Guillemare E, Ckoppola T, Sarret P and Vincent J. Structure, functional expression and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. Journal of Neuroscience. 1996. 16:5613-5620.
  56. Mazzocchi G, Malendowicz L, Rebuffat P, Gottardo G and Nussdorfer G. Neurotensin stimulates CRH and ACTH release by rat adrenal medulla in vitro. Neuropeptides. 1998. 31:8-11.
  57. Mendez M, Souaze F, Nagano M, Kelly P, Rostene W and Forgez P. High affinity neurotensin receptor mRNA distribution in rat brain and peripheral tissues. Analysis by quantitative RT-PCR. Journal of Molecular Neuroscience. 1997. 9:93-102.
  58. Moody T, Mayr C, Gillespie T and Davis T. Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides. 1998. 19:253-258.
  59. Morin A and Beaudet A. Origin of the neurotensinergic innervation of the rat basal forebrain studied by retrograde transport of cholera toxin. Journal of Comparative Neurology. 1998. 391:30-41.
  60. Morin AJ. Tajani M. Jones BE. Beaudet A. Spatial relationship between neurotensinergic axons and cholinergic neurons in the rat basal forebrain: a light microscopic study with three-dimensional reconstruction. Journal of Chemical Neuroanatomy. 1996. 10:147-156.
  61. Nakamura H, Seto T, Nagase H, Yoshida M, Hatta K, Matsuzaki I and Ogino K. Involvement of central neurotensin in thermoregulatory and neuroimmune function in pregnant rats exposed to heat. Brain, Behavior, & Immunity. 1997. 11:141-152.
  62. Nicot A, Rowe WB, De Kloet E, Betancur C, Jessop D, Lightman S, Quirion R, Rostene W and Berod A. Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. Journal of Neuroendocrinology. 1997. 9:263-269.
  63. Nouel D, Faure M, St Pierre J, Alonso R, Quirion R and Beaudet A. Differential binding profile and internalization process of neurotensin via neuronal and glial receptors. Journal of Neuroscience. 1997. 17:1795-1803.
  64. Ortego J and Coca-Prados M. Molecular characterization and differential gene induction of the neuroendocrine-specific genes neurotensin, neurotensin receptor, PC1, PC2, and 7B2 in the human ocular ciliary epithelium. Journal of Neurochemistry. 1997. 69:1829-1839.
  65. Pellissier S, Eribon O, Chabert J, Gully D and Roche M. Peripheral neurotensin participates in the modulation of pre- and postprandial intestinal motility in rats. Neuropeptides 1996. 30:412-419.
  66. Poinot-Chazel C, Portier M, Bouaboula M, Vita N, Pecceu F, Gully D, Monroe J, Maffrand JP, Le Fur G and Casellas P. Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochemical Journal. 1996. 320:145-151.
  67. Pothoulakis C, Castagliuolo I and Leeman S. Neuroimmune mechanisms of intestinal responses to stress. Role of corticotropin-releasing factor and neurotensin. Annals of the New York Academy of Sciences. 1998. 840:635-648.
  68. Reubi J, Waser B, Friess H, Buchler M and Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998. 42:546-550.
  69. Rompre P, Boye S and Moisan J. Activation of neurotensin receptors in the prefrontal cortex stimulates midbrain dopamine cell firing. European Journal of Pharmacology. 1998. 341:169-172.
  70. Rompre P. Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine. European Journal of Pharmacology. 1997. 328:131-134.
  71. Rostene W and Alexander M. Neurotensin and neuroendocrine regulation. Frontiers in Neuroendocrinology. 1997. 18:115-173.
  72. Rostene W, Azzi M, Boudin H, Lepee I, Souaze F, Mendez-Ubach M, Betancur C and Gully D. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Annals of the New York Academy of Sciences. 1997. 814:125-141.
  73. Rovere C, Barbero P, Maoret J, Laburthe M and Kitabgi P. Pro-neurotensin/neuromedin N expression and processing in human colon cancer cell lines. Biochemical & Biophysical Research Communications. 1998. 246:155-159.
  74. Rowe W, Nicot A, Sharma S, Gully D, Walker C, Rostene W, Meaney M and Quirion R. Central administration of the neurotensin receptor antagonist, SR48692, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity. Neuroendocrinology. 1997. 66:75-85.
  75. Sahu A. Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology. 1998. 139:795-798.
  76. Saleh T, Kombian S, Zidichouski J and Pittman Q. Cholecystokinin and neurotensin inversely modulate excitatory synaptic transmission in the parabrachial nucleus in vitro. Neuroscience. 1997. 77:23-35.
  77. Saleh T. Visceral afferent stimulation-evoked changes in the release of peptides into the parabrachial nucleus in vivo. Brain Research. 1997. 778:56-63.
  78. Santucci V, Gueudet C, Steinberg R, Le Fur G and Soubrie P. Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Synapse. 1997. 26:370-380.
  79. Sarhan S, Hitchcock J, Grauffel C and Wettstein J. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides. 1997. 18:1223-1227.
  80. Sarret P, Beaudet A, Vincent J and Mazella J. Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. Journal of Comparative Neurology. 1998. 394:344-356.
  81. Schaeffer P, Laplace M, Bernat A, Prabonnaud V, Gully D, Lespy L and Herbert J. SR142948A is a potent antagonist of the cardiovascular effects of neurotensin. Journal of Cardiovascular Pharmacology. 1998. 31:545-550.
  82. Seethalakshmi L, Mitra SP, Dobner PR, Menon M and Carraway R. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate. 1997. 31:183-192.
  83. Seufferlein T and Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Research. 1996. 56:5758-5764.
  84. Sharma R, Janicak PG, Bissette G and Nemeroff CB. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. American Journal of Psychiatry. 1997. 154:1019-1021.
  85. Shearman L and Weaver D. Haloperidol regulates neurotensin gene expression in striatum of c-fos-deficient mice. Molecular Brain Research. 1997. 47:275-285.
  86. Singh J, Desiraju T and Raju T. Effects of microinjections of cholecystokinin and neurotensin into lateral hypothalamus and ventral mesencephalon on intracranial self-stimulation. Pharmacology, Biochemistry & Behavior. 1997. 58:893-898.
  87. Smith D, Hawranko A, Monroe P, Gully D, Urban M, Craig C, Smith J and Smith D. Dose-dependent pain-facilitatory and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. Journal of Pharmacology & Experimental Therapeutics. 1997. 282:899-908.
  88. Souaze F, Rostene W and Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. Journal of Biological Chemistry. 1997. 272:10087-10094.
  89. Stiller C, Gustafsson H, Fried K and Brodin E. Opioid-induced release of neurotensin in the periaqueductal gray matter of freely moving rats. Brain Research. 1997. 774:149-158.
  90. Stoessl A, James K and Napier B. The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat. Neuropharmacology. 1997. 36:93-99.
  91. Svenningsson P, Georgieva J, Kontny E, Heilig M and Fredholm B. Involvement of a c-fos-dependent mechanism in caffeine-induced expression of the preprotachykinin A and neurotensin/neuromedin N genes in rat striatum. European Journal of Neuroscience. 1997. 9:2135-2141.
  92. Tremblay M, Rouillard C and Levesque D. Dopamine D3 receptor antisense reduces neuropeptide mRNA levels in rat nucleus accumbens. Neuroreport. 1997. 8:3901-3905.
  93. Tyler B, Cusack B, Douglas C, Souder T and Richelson E. Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Research. 1998. 792:246-252.
  94. Tyler B, Groshan K, Cusack B and Richelson E. In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine, antagonize neurotensin-mediated antinociception. Brain Research. 1998. 787:78-84.
  95. Tyler B, McKormick D, Hoshall C, Douglas C, Jansen K, Lacy B, Cusack Band Richelson E. Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Letters. 1998. 421:280-284.
  96. Udupi V, Townsend C and Greeley G. Stimulation of prohormone convertase-1 mRNA expression by second messenger signaling systems. Biochemical & Biophysical Research Communications. 1998. 246:463-465.
  97. Urban M and Gebhart G. Characterization of biphasic modulation of spinal nociceptive transmission by neurotensin in the rat rostral ventromedial medulla. Journal of Neurophysiology. 1997. 78:1550-1562.
  98. Vanneste Y, Thome A, Vandersmissen E, Charlet C, Franchimont D, Martens H, Lhiaubet A, Schimpff R, Rostene W and Geenen V. Identification of neurotensin-related peptides in human thymic epithelial cell embranes and relationship with major histocompatibility complex class I molecules. Journal of Neuroimmunology. 1997. 76:161-166.
  99. Vincent B, Jiracek J, Noble F, Loog M, Roques B, Dive V, Vincent J and Checler F. Contribution of endopeptidase to central neurotensin inactivation. European Journal of Pharmacology. 1997. 334:49-53.
  100. Vincent B, Jiracek J, Noble F, Loog M, Roques B, Dive V, Vincent J and Checler F. Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase on neurotensin-induced analgesia and neuronal inactivation. British Journal of Pharmacology. 1997. 121:705-710.
  101. Wagstaff J, Gibb J and Hanson G. Role of dopamine D1- and NMDA receptors in regulating neurotensin release in the striatum and nucleus accumbens. Brain Research. 1997. 748:241-244.
  102. Wang H. A site-directed mutagenesis study on the conserved alanine residue in the distal third intracellular loops of cholecystokininB and neurotensin receptors. British Journal of Pharmacology. 1997. 121:310-316.
  103. Watters J and Dorsa D. Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms. Journal of Neuroscience. 1998. 18:6672-6680.
  104. Weatherspoon J, Frank A, Werling L. Neurotensin, N-acetyl-aspartylglutamate and beta-endorphin modulate [3H]dopamine release from guinea pig nucleus accumbens, prefrontal cortex and caudate-putamen. Neuropeptides. 1996. 30:497-505.
  105. Xing L, Karinch A and Kauffman G. Mesolimbic expression of neurotensin and neurotensin receptor during stress-induced gastric mucosal injury. American Journal of Physiology. 1998. 274:R38-45.
  106. Yamada M, Yamada M, Lombet A, Forgez P and Rostene W. Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Life Sciences. 1998. 62:PL 375-380.

Back to Chapter

published 2000